Cat. No.: DAB-0012087
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human GPAT4 protein. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | GPAT4 |
| UniProt No. | Q86UL3 |
| Gene ID | 137964 |
| Gene Description | Glycerol-3-phosphate acyltransferases catalyze the first step in the de novo synthesis of triacylglycerol and phospholipids by converting glycerol-3-phosphate to lysophosphatidic acid. The GPAT family consists of four family members: two mitochondrial proteins and two microsomal proteins. Each can differ in tissue expression, regulation, and physiological and pathophysiological roles. The microsomal proteins GPAT3 and GPAT4 were originally designated as AGPAT8 and AGPAT6, respectively. 1-acyl-glycerol-3-phosphate acyltransferase catalyzes the subsequent reaction converting LPA to phosphatidic acid. The genes were renamed to GPAT3 and GPAT4 upon elucidation of GPAT activity. Both GPAT3 and GPAT4 are expressed in adipose tissue, but GPAT3 is highly induced during adipocyte differentiation. Brown adipose tissue preferentially expresses GPAT4. GPAT3 and GPAT4 may also be phosphorylated in response to insulin treatment to increase GPAT activity. Accumulation of saturated LPA produced by GPAT4 at the ER-mitochondrial contact site can inhibit autophagy through the abnormal formation of omegasomes, which are precursors to the autophagosome. Glycerolipid synthesis by GPAT3 and GPAT4 can also regulate activation of macrophages. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
